Moleculin announces COVID-19 drug collaboration Moleculin Biotech has inked an agreement with the University of Campinas in São Paulo, Brazil, to collaborate on researching the antiviral capabilities of WP1122, its COVID-19 drug candidate.
Takeda expands COVID-19 vaccine supply with Moderna, Japan Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.
GCAR begins COVID-19 clinical trials The Global Coalition for Adaptive Research (GCAR) said that the first patient has been enrolled in an adaptive multicenter clinical trial to test interventions for hospitalized COVID-19 patients.
Nektar plans clinical trial for COVID-19 treatment Nektar Therapeutics has received clearance from the U.S. Food and Drug Administration for an investigational new drug application for its interleukin-2 pathway agent NKTR-214 (Bempegaldesleukin) for evaluation in a phase IB clinical study in adult patients with mild COVID-19 infection.
Who should get the 1st COVID-19 vaccines? Once a vaccine for SARS-CoV-2 is approved by the U.S. Food and Drug Administration to be administered to the public, who should receive it first, given that its supply will be initially limited? A new perspective published in Science on October 21 fleshes out different COVID-19 vaccine distribution strategies that would ensure optimal protection from the disease under conditions of vaccine scarcity. Discuss